4,876 reports of this reaction
3.4% of all PEGINTERFERON ALFA 2A reports
#4 most reported adverse reaction
RASH is the #4 most commonly reported adverse reaction for PEGINTERFERON ALFA 2A, manufactured by pharmaand GmbH. There are 4,876 FDA adverse event reports linking PEGINTERFERON ALFA 2A to RASH. This represents approximately 3.4% of all 141,362 adverse event reports for this drug.
PEGINTERFERON ALFA 2A has an overall safety score of 85 out of 100. Patients taking PEGINTERFERON ALFA 2A who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is moderately reported among PEGINTERFERON ALFA 2A users, representing a notable but not dominant share of adverse events.
In addition to rash, the following adverse reactions have been reported for PEGINTERFERON ALFA 2A:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 4,876 FDA reports for PEGINTERFERON ALFA 2A. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 3.4% of all adverse event reports for PEGINTERFERON ALFA 2A, making it a notable side effect.
If you experience rash while taking PEGINTERFERON ALFA 2A, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.